---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic burden and healthcare resource utilization. Topics: US claims, 5,940 females: all-cause and Rett-related healthcare resource utilization; US claims, 5,940 females: all-cause and Rett-related healthcare costs; US claims, 5,940 females: data source and cost limitations; US claims, 5,940 patients: cost of gastrointestinal manifestations; 9 further topics. 13 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### US claims, 5,940 females: all-cause and Rett-related healthcare resource utilization

> “Among 5,940 female patients (pediatric: 3,078; adult: 2,862) with mean observation period of 2.04 years, the most prevalent clinical manifestations were neurological disorders (72.8%), gastrointestinal/nutritional disorders (41.9%), and orthopedic disorders (34.6%).”
> “The incidence rate of all-cause HRU by place of service among female patients with RTT was 44.43 visits PPPY during the observation period, primarily driven by home/hospice care (16.31 visits PPPY), OP visits (9.58 visits PPPY), and therapeutic service visits (7.26 visits PPPY; Table 6).”
> “All-cause HRU largely comprised of RTT-related HRU, with 47% of the all-cause incidence rate attributed to a RTT diagnosis in the overall study population (Table 6).”
> “Trends were similar by subgroup; although, rates of HRU were generally higher among pediatric patients relative to adult patients (all-cause: 52.43 and 35.86, respectively), which translated into higher mean healthcare costs (all-cause: $45,718 and $34,548, respectively).”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.8.2-2"></a>

### US claims, 5,940 females: all-cause and Rett-related healthcare costs

> “Mean all-cause healthcare costs were $40,326 per-patient-per-year, with medical costs driven by home/hospice care visits, therapeutic services, outpatient visits, and inpatient visits.”
> “RTT-related healthcare costs comprised 45% of all-cause healthcare costs.”
> “During the observation period, female patients with RTT incurred mean all-cause total healthcare costs of $34,772 (86%) in pre-adjudicated medical costs and $5,554 (14%) in adjudicated pharmacy costs (Table 7).”
> “Mean all-cause medical costs were primarily driven by home/hospice care visits ($12,054), followed by therapeutic services ($7,071), OP visits ($6,791), and inpatient visits ($6,088) among the overall cohort.”
> “Mean RTT-related total healthcare costs PPPY included $14,643 in pre-adjudicated medical costs and $3,428 in adjudicated pharmacy costs (Table 7).”
> “All costs were inflation-adjusted to 2021 US dollars (USD).”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.8.2-3"></a>

### US claims, 5,940 females: data source and cost limitations

> “Administrative healthcare claims data from the IQVIA™ Medical Claims Data (Dx) and Longitudinal Prescription Data (LRx) databases (11/1/2016–10/31/2019) were used to address the study objectives.”
> “This analysis relied on pre-adjudicated medical claims from IQVIA Dx database, for which payment amounts have not yet been finalized and are often inflated compared to their adjudicated equivalent. Therefore, healthcare costs may be overestimated.”
> “For example, overall coverage of institutional claims is lower than that of OP claims in the IQVIA Dx database, potentially resulting in incomplete capture of inpatient, ED, and long-term care/skilled nursing facility visits.”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.8.2-4"></a>

### US claims, 5,940 patients: cost of gastrointestinal manifestations

> “Mean medical costs of managing GI manifestations amounted to $4473 per patient per year (PPPY) and were somewhat higher in pediatric ($5530 PPPY) than adult ($3341 PPPY) patients.”
> “GERD was associated with the highest mean medical cost ($2630 PPPY), of which the largest component was the cost of therapeutic services (including physical therapy, hydrotherapy, occupational therapy, speech therapy, and feeding assistance), which amounted to $1071 PPPY (SD: $8264).”
> “The second most costly manifestation to manage was constipation ($923 PPPY), which mean cost PPPY was higher in pediatric than adult patients ($1010 vs $830, respectively).”
> “Mean medical costs were reported per patient per year (PPPY) to account for varying lengths of follow-up and inflation-adjusted to 2021 US dollars.”

Source: [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)

<a id="topic-2.2.1.8.2-5"></a>

### Australian population: health sector costs converted to US dollars

> “While we have identified no studies reporting specifically on the costs of managing GI manifestations in RTT, in an analysis of the Australian Rett Syndrome Database, mean healthcare costs associated with RTT management overall were estimated at AUD 21,158 PPPY (equivalent to USD 25,691 as of December 2022 [14,15]), and ranged from AUD 238 to AUD 85,776 (equivalent to USD 289 to USD 104,151 [14,15]) [16], also suggesting substantial between-patient variability in the healthcare costs incurred.”

Source: [May et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10842289/)

<a id="topic-2.2.1.8.2-6"></a>

### US Natural History Study registry, 455 females: hospital and emergency room visits and gastrostomy

> “Over a median follow-up period of 4 years, nearly half (44.6%) of all individuals had a hospital or emergency room visit (Fig. 2), with a significantly higher proportion of visits observed in individuals with classic RTT than atypical RTT (47.1% vs. 20.9%, p = 0.001), and pediatric individuals than adult individuals (48.5% vs. 29.3%, p = 0.001) (Supplementary Table 2).”
> “Incident g-tube surgeries were observed among 13.7% of individuals, and pediatric individuals had a significantly higher incidence of g-tube surgery than adult individuals (16.7% vs. 2.7%, p = 0.002) (Supplementary Table 2).”

Source: [May et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11282812/)

<a id="topic-2.2.1.8.2-7"></a>

### Ontario, Canada, population data: healthcare touchpoints

> “In total, 246 RTT cases were indexed; 40% from central Ontario, 95% female, median age 21 years.”
> “Most patients had at least one outpatient visit (primary care 96.7%, specialist 86.6%), emergency department visit (76.8%) and inpatient hospitalization (54.5%).”
> “During the 5-year follow-up period, most cases (95.1%) had at least one public claim for all-cause medication.”

Source: [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/)

<a id="topic-2.2.1.8.2-8"></a>

### Epilepsy: emergency department visits and inpatient admissions at a US Rett center

> “In this analysis, 98 individuals with RTT were included: 71 (72%) had epilepsy of which 33 (46%) had severe epilepsy.”
> “Comparing all-cause HCRU during the 12-month follow up period (Figure 3), the prevalence of ED visits was significantly higher among those with severe epilepsy vs. those with non-severe epilepsy (27% vs. 7%, p < 0.05). Inpatient admissions were also significantly more prevalent among those with severe epilepsy vs. non-severe epilepsy (37% vs. 14%, p < 0.05).”
> “In the year following diagnosis, epilepsy-specific inpatient admissions were documented for 12 (20%) and ED visits for 4 (7%) of the 59 individuals with epilepsy (Figure 4).”

Source: [Rashid et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12549289/)

<a id="topic-2.2.1.8.2-9"></a>

### Aspiration: inpatient admissions at a US Rett center

> “Of eligible individuals, 25 (28.1%) were aspiration cases.”
> “Aspiration cases were also significantly twice more likely to have ≥ 1 inpatient admissions for any reason than non-aspiration controls (75.0% vs. 35.0%, p < 0.05). Rates of all-cause outpatient visits and ED visits were similar among the two groups; however, the number of inpatient admissions were higher for the aspiration cases vs. non-aspirating controls (9.4 vs. 2.6, ns), (Table 2).”

Source: [Rashid et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12082938/)

<a id="topic-2.2.1.8.2-10"></a>

### Respiratory infection: hospital admissions in an international registry

> “A hospital admission for LRTI over the previous 5 years was reported for slightly more than one-fifth (21.4%) of individuals.”
> “Compared with independent walking, being unable to walk was associated with a sixfold increased risk (adjusted relative risk 6.73, 95% CI 3.42-13.25), with assisted walking associated with an intermediate risk.”

Source: [MacKay et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29536504/)

<a id="topic-2.2.1.8.2-11"></a>

### Scoliosis surgery: inpatient length of stay and complications in the Kids' Inpatient Database

> “Using the International Classification of Diseases Ninth and 10th revision codes in the national Kids' Inpatient Database, we identified children with RTT who underwent PSF from 2000 to 2019.”
> “RTT diagnosis independently predicted higher odds of any complications (odds ratio: 1.98, P < 0.001) and increased length of stay (odds ratio: 1.18, P = 0.009) for admissions for PSF.”
> “The higher Elixhauser Comorbidity Index in RAS patients predicted higher costs, longer hospital stays, more complications (particularly respiratory), and more nonroutine discharge disposition than in other patients with NMS.”

Source: [Stone et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37642479/)

<a id="topic-2.2.1.8.2-12"></a>

### Scoliosis surgery: length of stay, readmissions, and reoperations at one US center

> “The median estimated blood loss was 600 mL and length of stay was 7 days.”
> “There were 3 readmissions (12%) within 30 days for pneumonia and 2 (8%) reoperations (an incision and drainage and C2-T2 fusion for significant kyphosis) within 90 days.”

Source: [Taylor et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36882895/)

<a id="topic-2.2.1.8.2-13"></a>

### Systematic literature review: cost and resource use evidence

> “Data were extracted from relevant publications reporting on clinical (n=40), humanistic (n=32), and cost/HCRU (n=11) outcomes (Figure 1).”
> “Limited cost data were available in the literature, but where comparative data were reported, healthcare costs associated with Rett syndrome were higher than healthcare costs for the general population. Residential care, home/hospice care visits, therapeutic services, and outpatient and inpatient visits were the main cost drivers.”
> “Furthermore, the absence of pharmacoeconomic models and comprehensive estimates of the total economic burden is noteworthy.”

Source: [May et al. (2024b)](https://acadia.com/en-us/pdf/healthcare-professionals/scientific-publications/congress-materials/2024_EAN_May_HTA_SLR_Pos.pdf)

Additional sources: [Hendrie et al. (2011)](https://doi.org/10.1016/j.rasd.2010.10.004); [Lotan (2019)](https://pubmed.ncbi.nlm.nih.gov/30644545/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
